SXTP VS AVGR Stock Comparison
Performance
SXTP10/100
10/100
SXTP returned -82.63% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
AVGR10/100
10/100
AVGR returned -79.08% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Profit
SXTP10/100
10/100
Out of the last 4 quarters, SXTP has had 0 profitable quarters and has increased their profits year over year on 0 of them.
AVGR10/100
10/100
Out of the last 20 quarters, AVGR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
SXTP38/100
38/100
SXTP has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.
AVGR27/100
27/100
AVGR has had a lower than average amount of volatility over the last 12 months giving it a score of 27 of 100.
Analyst Price Targets
SXTP
"Analyst Price Targets" not found for SXTP
AVGR75/100
75/100
1 analysts offer 12-month price targets for AVGR. Together, they have an average target of 0, the most optimistic target put AVGR at 0 within 12-months and the most pessimistic has AVGR at 0.
Technicals
SXTP
"Technicals" not found for SXTP
AVGR18/100
18/100
AVGR receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.
Earnings
SXTP
"Earnings" not found for SXTP
AVGR10/100
10/100
AVGR has missed earnings 11 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
60 Degrees Pharmaceuticals, Inc. Common Stock Summary
Nasdaq / SXTP
Healthcare
Biotechnology
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Avinger, Inc. Common Stock Summary
Nasdaq / AVGR
Healthcare
Medical - Instruments & Supplies
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare SXTP to other companies in the same or a similar industry.